REG - LungLife AI, INC - VA sites in validation study; SAB appointment

LungLife AIAnnouncement

17/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220317:nRSQ0437Fa&default-theme=true

RNS Number : 0437F  LungLife AI, INC  17 March 2022

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Veterans Affairs (VA) sites added to validation study with first Veteran
enroled

Key lung cancer specialist, Dr Drew Moghanaki, appointed to Scientific
Advisory Board

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces its pivotal clinical study to evaluate the LungLB® test
will now include multiple VA medical centres, of which the first participant
has been enroled from the Bay Pines VA in Florida.

 

The VA has the United States' largest integrated health care system, providing
care at nearly 1,300 facilities and serving 9 million veterans each year. Lung
cancer is the leading cause of cancer-related deaths among US veterans, and it
is believed that veterans are at higher risk in part due to environmental
exposures during military service. An estimated 900,000 US veterans are
at-risk for lung cancer, and VA hospitals diagnose around 7,700 new lung
cancer cases each year.

 

The Company also announces the appointment of Dr Drew Moghanaki, MD, MPH, to
its Scientific Advisory Board, who is an internationally recognised lung
cancer specialist. He is Professor and Chief of Thoracic Oncology at the UCLA
Department of Radiation Oncology. Dr Moghanaki brings extensive leadership to
the Scientific Advisory Board as the Director of the VA Partnership to
increase Access to Lung Cancer Screening programme (VA-PALS), and the co-chair
of the VA Lung Cancer Surgery or Stereotactic Radiotherapy (VALOR) Phase III
study, investigating treatment options for stage I lung cancer. Dr Moghanaki
is also Staff Physician at the Greater Los Angeles VA Healthcare System.

 

Dr Drew Moghanaki, MD, MPH, Scientific Advisory Board member at LungLife,
said: "Blood-based testing to facilitate early detection of lung cancer would
be a welcomed advance as the majority of lung cancers continue to be diagnosed
in later stages. I am pleased to be joining LungLife's Scientific Advisory
Board and look forward to working with them to unlock the full potential of
the LungLB® test."

 

Paul Pagano, Chief Executive Officer of LungLife, said: "I am delighted that
we will have representation from the VA Healthcare System in our study, as
this marks an important step on our journey towards the successful deployment
of the LungLB® test. Dr Moghanaki brings with him significant experience in
early detection and treatment of lung cancer which will further strengthen our
Scientific Advisory Board."

 

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Daniel Adams / Virginia Bull / Cameron MacRitchie

 Walbrook PR Limited                                  Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                     (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings / Phillip Marriage    Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

About Lunglife AI

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUNABRUAUOAAR